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Abstract
Background: The essential amino acid tryptophan cannot be synthesised in the body and must be acquired
through dietary intake. Oxidation of tryptophan, due to immune induction of the enzyme indoleamine 2,3-
dioxygenase (IDO), is considered to be the main cause of tryptophan depletion in HIV infection and AIDS.
We examined plasma tryptophan levels in a low-income sub-Saharan HIV-infected population and compared it to
that of developed countries. Tryptophan levels were further examined in context of the general nutritional and
inflammatory status.
Methods: This cross-sectional study included 105 HIV-positive patients recruited from the Kalafong Hospital in
Pretoria, South Africa, and 60 HIV-negative controls.
Results: Patient tryptophan levels were in general markedly lower than those reported for developed countries. In
contrast to reports from developed countries that showed tryptophan levels on average to be 18.8 % lower than
their control values, tryptophan levels in our study were 44.1 % lower than our controls (24.4 ± 4.1 vs. 43.6 ±
11.9 μmol/l; p < 0.001). Tryptophan levels correlated with both CD4 counts (r = 0.341; p = 0.004) and with pro-
inflammatory activity as indicated by neopterin levels (r = −0.399; p = 0.0001). Nutritional indicators such as albumin
and haemoglobin correlated positively with tryptophan and negatively with the pro-inflammatory indicators
neopterin, interleukin 6 and C-reactive protein. The most probable causes of the lower tryptophan levels seen in
our population are food insecurity and higher levels of inflammatory activity.
Conclusions: We contend that inflammation-induced tryptophan depletion forms part of a much wider effect of
pro-inflammatory activity on the nutritional profile of HIV-infected patients.
Keywords: Tryptophan, HIV/AIDS, Malnutrition, Sub-Saharan, Pro-inflammatory activity
Background
Tryptophan, as an essential amino acid, cannot be syn-
thesised in the body and must be acquired through in-
take and from tryptophan released during protein
turnover [1]. A daily nutritional intake at around
20 mmol is said to be required to sustain normal plasma
levels [2]. The majority of tryptophan is utilised for the
synthesis of tissue proteins [3], whereas about 1 % of
dietary tryptophan serves as a substrate for the biosyn-
thesis of serotonin [2, 4]. Tryptophan is also used for the
de novo synthesis of niacin and is said to play a role in
the immune regulation of normal T-cell function [5–7].
Excess tryptophan, i.e., at levels above the requirement
for protein and serotonin synthesis, is oxidised in the
liver under influence of the liver-specific enzyme L-tryp-
tophan 2,3-dioxygenase (TDO), to ATP, CO2, and water.
In contrast, tryptophan oxidation under influence of the
inflammation-inducible enzyme indoleamine 2,3-dioxy-
genase (IDO) occurs in various cell types and is not lim-
ited by a decrease in tryptophan levels [6, 7]. Two forms
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of indoleamine 2,3-dioxygenase exist, i.e., indoleamine
2,3-dioxygenase-1 and indoleamine 2,3-dioxygenase-2,
with subtle differences in substrate specificity and inhib-
ition characteristics [7].
Tryptophan depletion in HIV infection and AIDS has
been described previously [6, 8–20]. However, these re-
sults are generally based on populations from developed
countries. In developed countries, oxidation of trypto-
phan along the kynurenine pathway, under influence
of the rate-limiting enzyme IDO, is considered to be
the main cause of tryptophan depletion in HIV and
AIDS [5, 6, 8, 9]. This study examined tryptophan
levels in a black, low-income population from the
Gauteng Province, South Africa, and compared it to
that reported for populations from developed coun-
tries. The study further examined tryptophan deple-
tion in context of the inflammatory and general
nutritional status of HIV-infected patients.
Methods
A group of 105 HIV-positive adult (>18 years old) black
patients were recruited from the Immunology Clinic at
Kalafong Secondary Hospital which provides health ser-
vices predominantly to communities of Atteridgeville
and surrounding areas west of Pretoria. Although the
patients lived predominantly in Atteridgeville, they were
mostly born outside of the township and it is estimated
that about one third are immigrants from other African
countries. They are generally of low income, with poor
housing, and many are unemployed. Some families sur-
vive on a single grant or pension. Maize meal is the
staple diet of the population, but a tendency to convert
to fast foods occurs when their socio-economic status al-
lows. Sixty-four percent (64 %) of the highly active anti-
retroviral treatment (HAART) group, 60 % of the
HAART naïve group and 63 % of the control group were
female. The mean ages of the different groups (HAART
37.9 ± 8.9; naïve 37.1 ± 10.2; and controls 31.2 ± 8.1 years)
were not statistically different.
Patients were on antiretroviral treatment for an aver-
age period of 15.9 ± 16.5 months. At the time of sample
collection, triple therapy was given, mostly efavirenz
(EFV)/nevaripine (NVP), lamuvidine (3TC) and stavu-
dine (D4T). Presently, the clinic is converting to the
FDC (fixed drug combination: emtricitabine, tenofovir,
lamuvidine), single dose with apparently better patient
compliance. At baseline, 22.9 % of the total HIV patient
group were confirmed by sputum smears as TB positive.
TB-positive patients were treated with isoniazid (INH),
pyrazinamide (PZA), rifampicin (RIF) and ethambutol
(ETH) for at least 6 months depending on the sensitivity
of the TB organism. Although patients are initially edu-
cated as to a well-balanced healthy diet and their
weights are monitored, they do not have regular one-on-
one counselling with a dietician. The HIV patients were
divided into HAART (n = 75) and HAART naïve (n = 30)
groups. Patients were also subdivided according to co-
infection with TB (n = 24). Sixty HIV-negative controls
were recruited from the South African National Blood
Service (SANBS) satellite site based in Pretoria West.
This was a cross-sectional study based on the analysis
of patients’ blood samples. The study received ethical
approval, in accordance with the Declaration of Helsinki,
from the Faculty of Health Sciences Research and Ethics
Committee of the University of Pretoria (107/2008) and
from the South African National Blood Service Human
Research Committee (2010/03). Written or verbal in-
formed consent, as witnessed and formally recorded,
was obtained from all volunteers prior to participation
in this study. The study was conducted over a period of
2 years from January 2012.
Although patients were not instructed to fast over-
night, blood was drawn in the morning during the pa-
tients’ scheduled visit to the clinic. Plasma samples for
neopterin, IL-6, interferon-γ and tryptophan were proc-
essed on site and stored at −70 °C until analysis. Trypto-
phan was quantified by gas chromatography mass
spectrometry (GC-MS) using a method developed and
validated in our laboratory. Briefly, samples were proc-
essed and derivatized with pentafluoropropionic anhyd-
ride and pentafluoropropanol before analysis. Isotope
label deuterated tryptophan was used as the internal
standard. The GC oven was programmed to begin at an
initial temperature of 80 °C with a ramp at a rate of 20 °C
up to 180 °C followed by a 10 °C ramp up to a maximum
temperature of 280 °C. Sample peaks were eluted on a
DB-5MS capillary column within a chromatographic run-
time of 18 min using a Thermo Scientific Trace 1300 gas
chromatographer coupled to an ISQ single quadropole
mass spectrometer.
Neopterin was measured as the primary indicator of in-
flammatory activity. Neopterin, a catabolic product of the
purine nucleotide guanosine triphosphate, is produced
from guanosine 5′-triphosphate (GTP) that is cleaved by
GTP cyclohydrolase 1 to 7,8-dihydroneopterin triphos-
phate, followed by conversion of 7,8-dihydroneopterin tri-
phosphate to neopterin and 7,8-dihydroneopterin
under the influence of phosphatases [21]. GTP cyclo-
hydrolase 1 is stimulated, predominantly, by T-helper
cell type-1-derived interferon-γ, but co-stimulation by
tumour necrosis factor alpha may contribute [21].
Neopterin has been shown, both in our laboratories
and in that of others, to be an excellent indicator of
pro-inflammatory activity [13, 21, 22].
Neopterin was measured by sandwich ELISA accord-
ing to the manufacturer’s kit protocol (Immuno-Bio-
logical Laboratories Inc., USA). The pro-inflammatory
cytokines IL-6 and interferon-γ (IFN-γ) were determined
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using a cytometric bead array kit (BD Biosciences, San
Jose, CA, USA) and flow cytometry. All other laboratory
variables were determined by the National Health
Laboratory service (NHLS) at Kalafong.
Group comparisons were assessed by analysis of vari-
ance (ANOVA) following data collation testing for nor-
mality and log transformations. Because the data did not
show a normal distribution, the non-parametric Kruskal-
Wallis test was employed for comparisons between sub-
groups. Actual values are expressed as mean and standard
deviation. Non-parametric Spearman rank correlation co-
efficients were used to determine associations between
group variables. All analyses were performed at a signifi-
cance level of p < 0.05 using Statistical Package for Social
Sciences version 22 (SPSS, IBM, Endicott, NY, USA).
Results
The total patient group presented with a mean viral load
of 2.8 ± 1.4 log10 copies/ml and a CD4 count of 258.0 ±
193.1 cells/μl. The tryptophan level for the total patient
group (24.4 ± 4.1 μmol/l) was significantly (p < 0.0001)
lower than that of the control group (43.6 ± 11.9 μmol/
l). Patient tryptophan levels were thus almost half
(44.1 %) of that of the controls. Patients with a CD4
count of less than 200 cells/μl presented with signifi-
cantly lower tryptophan levels (23.0 ± 4.2 vs. 26.1 ±
4.1 μmol/l; p = 0.03) than patients with CD4 counts
greater than 200 cells/μl. The tryptophan levels in the
HAART naive group (22.0 ± 4.3 μmol/l) were signifi-
cantly (p = 0.03) lower than that of the HAART group
(25.1 ± 3.8 μmol/l). Tryptophan levels correlated with
both CD4 count and neopterin values for the total patient
(CD4 r = 0.341; p = 0.004, neopterin r = −0.399; p = 0.0001)
and HAART (CD4 r = 0.291; p = 0.04, neopterin r =
−0.359; p = 0.002) groups. Tryptophan levels were not
significantly different between the HIV patients with
TB (23.9 ± 4.9 μmol/l) and those without TB co-
infection (24.5 ± 3.9 μmol/l).
Tryptophan levels were subsequently compared to that
found in studies from developed countries (Table 1). Al-
though values from developed countries varied, trypto-
phan levels in patients of our study were in general
markedly lower.
Albumin (29.0 ± 8.0 vs. 37.5 ± 3.9 g/l; p < 0.001),
haemoglobin (10.7 ± 2.4 vs. 12.7 ± 1.9 g/dl; p = 0.001),
BMI (21.5 ± 5.6 vs. 25.4 ± 7.1 kg/m2; p = 0.02) and
Table 1 Comparison of tryptophan levels in HIV/AIDS patients of this study and that of developed countries
A B C D p value
Controls Total group ART—naïve ART







Werner et al. 1988 [10] (h) 91.0 44.8 (n = 11) - - <0.0001 (A–C)
Larsson et al. 1989 [11] (h) 39.7 (n = 14) 28.4 (n = 24) - - <0.05 (A–B)
Fuchs et al. 1990 [12] (h) 91.1 (n = 11) 48.8 dementia
70.5
- - <0.05 (A–B)
<0.01 (A–B)
Fuchs et al. 1990 [9] (h) 39.7 29.8 (n = 22) - - -
Fuchs et al. 1991 [13] (h) 91.0 57.0 (n = 42) (62 % naïve) (38 % on ART) <0.01 (A–B)
Heyes et al. 1992 [14] (h) 70.9 (n = 20) 40.2 (n = 107) - - <0.0001 (A–B)
Gisselen et al. 1994 [15] (h) - 29.4 (n = 14) 29.4 (pre-ART) 36.2 (post-ART) <0.01 (C–D)
Hortin et al. 1994 [16] (fl) 46 (n = 20) 22 (n = 20) - (85 % on ART) <0.001 (A–B)
Laurichesse et al. 1998 [17] (fl) 59 (n = 8) 51 (n = 7) - - <0.05 (A–B)
Huengsberg et al. 1998 [18] (h) 56.3 (n = 72) 50.1 (n = 82) - - <0.01 (A–B)
Look et al. 2000 [19] (gc) 52.6 (n = 55) 44.6 (n = 17)
37.4 (n = 7) AIDS
44.6 (pre-ART) 53.0 (post-ART) 0.14 (A–B)
0.009 (A–B)
0.039 (C–D)
Murray et al. 2001 [20] (h) 49.3 69.2 (post niacin treatment) - - -
Zangerle et al. 2002 [8] (h) 65.8 (n = 40) 44.1 (n = 45) 44.1 (pre-ART) 53.2 (post-ART) <0.001 (A–B)
<0.001 (A–D)
0.001 (C–D)
Schroeksnadel et al. 2008 [6] (h) - 51.4 (n = 152) - (70 % on ART) -
Analytical methods used: gc gas chromatography mass spectrometry, fl fluorometric procedure, h high-performance liquid chromatography
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albumin/globulin (A/G) ratio (0.5 ± 0.2 vs. 0.7 ± 0.2;
p < 0.0001) were significantly lower in patients with
CD4 counts less than 200 cells/μl. In Table 2, corre-
lations for the total group of patients are shown be-
tween tryptophan, CD4 counts, neopterin, IL-6, and
CRP levels, on the one hand, and albumin, globulin,
the albumin/globulin (A/G) ratio, haemoglobin, red
cell distribution width and body mass index (BMI),
on the other.
Patients with CD4 less than 200 cells/μl presented
with significantly elevated neopterin (70.5 ± 45.1 nmol/l
vs. 24.1 ± 20.9; p < 0.0001) as compared to patients with
CD4 counts greater than 200 cells/μl. The neopterin
levels of HIV patients in the present study were subse-
quently compared to that reported in developed coun-
tries (Table 3).
Discussion
Increased oxidation of tryptophan in the kynurenine
pathway is considered the major cause of tryptophan de-
pletion in HIV-infected and AIDS patients. Oxidative
metabolism of tryptophan along the kynurenine pathway
increases during inflammatory conditions and is regu-
lated by the rate-limiting enzyme IDO which is stimu-
lated by pro-inflammatory cytokines, predominantly
IFN-γ [7, 22]. Evidence for decreased tryptophan levels
in HIV patients from populations in developed countries
has been shown by several studies (Table 1). However, a
lack exists in information on tryptophan levels in HIV-
infected AIDS populations from sub-Saharan regions.
The present study investigated tryptophan levels in
context of the inflammatory and nutritional status in a
low-income, black South African HIV-infected popula-
tion. The results of this study confirmed tryptophan de-
pletion in patients with HIV. However, tryptophan levels
were markedly lower than that found in developed coun-
tries (Table 1). In contrast to reports from developed
countries that showed tryptophan levels on average to
be 18.8 % lower than control values (calculated from
values in Table 1), patient tryptophan levels in the
present study were 44.1 % lower. The degree of trypto-
phan depletion correlated with the decline in the CD4
count (r = 0.341; p = 0.005) and therefore with the degree
of immune deficiency. No differences were seen between
TB-positive and TB-negative HIV patients. However,
TB-positive patients were all on anti-TB treatment.
The study showed, in line with studies from developed
countries (Table 1), tryptophan to be significantly lower
in the treatment naïve patients than in patients on
HAART. In view of the role of inflammatory activity in
the degradation of tryptophan and the lower levels of in-
flammation seen in the HAART than the HAART-naïve
group, depicted by neopterin and perhaps IL-6 and CRP,
it is reasonable to assume the higher tryptophan levels
in HAART patients to be the results of a partial correc-
tion of the HIV/AIDS-induced inflammatory activity in
patients treated with antiretrovirals. Tryptophan levels
were subsequently compared to the degree of pro-
inflammatory activity as reflected by levels of the pro-
inflammatory cytokines IL-6, IFN-γ, the acute phase
protein CRP and with neopterin. Tryptophan correlated
inversely with neopterin (r = −0.399; p = 0.0001) and IL-6
(r = −0.230; p = 0.026). The decline in tryptophan levels
with increases in inflammatory activity is in agreement
with evidence from previous studies [8, 13]. Perhaps of
greater importance is the fact that the decline in trypto-
phan levels correlated with increases in the levels of the
pro-inflammatory cytokine IFN-γ (r = −0.217; p = 0.036),
the major stimulus for indoleamine 2,3-dioxygenase.
Several factors may contribute to lower tryptophan
levels in low-income sub-Saharan HIV-infected and
AIDS populations when compared to levels found in
populations from developed countries, the most import-
ant probably food insecurity, but a higher degree of in-
flammation could potentially also contribute.
Food insecurity as a possible reason for tryptophan
depletion
Malnutrition is considered a worldwide phenomenon in
HIV, especially where it has progressed to AIDS [23].
Table 2 Correlations for the total group of patients between albumin, globulin, the albumin/globulin (A/G) ratio, haemoglobin, red
cell distribution width and BMI, on the one hand, and tryptophan, CD4 counts, neopterin, IL-6, and CRP levels, on the other
Tryptophan (μM) CD4 count (cells/μl) Neopterin (nmol/l) IL-6 (pg/ml) CRP (mg/l)
Rho p value Rho p value Rho p value Rho p value Rho p value
Albumin (g/l) 0.357* 0.001 0.491* <0.0001 −0.584* <0.0001 −0.274* 0.009 −0.442* <0.0001
Globulin (g/l) −0.321* 0.001 −0.271* 0.020 0.351* 0.0004 0.177 0.074 0.378* 0.0002
A/G ratio 0.385* 0.0003 0.486* <0.0001 −0.539* <0.0001 −0.225* 0.033 −0.468* <0.0001
Hb (g/dl) 0.378* 0.0003 0.420* 0.0003 −0.576* <0.0001 −0.193 0.063 −0.250* 0.020
RDW (%) −0.319* 0.003 −0.307* 0.001 0.334* 0.001 0.044 0.676 0.136 0.212
BMI (kg/m2) 0.154 0.157 0.368* 0.004 −0.317* 0.003 −0.360* 0.001 −0.066 0.573
A/G albumin to globulin ratio, Hb haemoglobin, RDW red cell distribution width, BMI body mass index
Spearman Rho correlation significant, *p < 0.05
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Several factors in HIV infection and AIDS can poten-
tially contribute to this state of malnutrition, including
nutrient availability, gastrointestinal problems (such as
diarrhoea, dysphagia, odynophagia, nausea, vomiting,
gastrointestinal bleeding and neoplasias), suppressed ap-
petite and altered metabolic processes such as increases
in metabolic rate, increased protein catabolism and in-
creases in nutritional requirements [23].
In addition to the conditions mentioned above for
HIV-infected and AIDS patients in general, additional
factors exist in low-income populations of developing
countries that may influence the nutritional status and
by implication, tryptophan levels in such patients. Mal-
nutrition, irrespective of HIV status, is a common fea-
ture in many populations of Africa [24]. According to
the 2012 Global Hunger Index, South Africa is ranked
ninth in the world for highest hunger levels [25]. Major
causes of the widespread malnutrition include limited
food or financial resources and poor nutritional value of
available food [24]. An additional contributing factor
may be dietary changes upon urbanisation. South Africa
is in a rural-to-urban transition phase, a phenomenon
often associated with a shift towards energy-dense foods
poor in proteins and amino acids [26, 27].
In developed countries, the dietary availability of tryp-
tophan would appear not to be a major problem [5].
While the average daily intake of tryptophan in devel-
oped countries is estimated to be around 1 g, the esti-
mated daily requirement is said to be between 175 and
250 mg [5]. This would leave a fair safety margin in
HIV-infected and AIDS populations with adequate nutri-
tional resources. However, the same cannot be said for
low-income sub-Saharan populations. Reports from dif-
ferent sub-Saharan populations vary, but the overriding
consensus appears to be that the prevalence of malnutri-
tion is exacerbated in HIV and AIDS due to factors such
as lack of employment income, stigmatisation and other
social determinants that contribute to household food
insecurity [28–34]. In the present study, maize meal rep-
resented the staple diet for the majority of patients—a
diet shown in a previous South African study to have a
negative impact on the nutritional status of HIV-infected
patients [35]. In view of the prevalence of malnutrition
in the general population and the contribution of HIV
and AIDS to household food insecurity, it seems feasible
to assume that malnutrition may be a contributor to the
differences found between tryptophan levels in the pa-
tients of this study and those from developed countries.
Higher inflammatory activity as a contributor to a greater
degree of tryptophan depletion in sub-Saharan
populations
Oxidation in the kynurenine pathway, under influence of
the enzyme IDO, is primarily driven by pro-inflammatory
activity [7, 13]. When the levels of pro-inflammatory activ-
ity, i.e. neopterin, in this study were compared to that of
HIV populations from the developed world, it was seen
that, at comparable CD4 counts, neopterin levels were
much higher in our patients (Table 3). This and the in-
verse correlations found between neopterin and trypto-
phan levels (r = −0.399; p = 0.0001) thus support the
notion of higher pro-inflammatory activity, and by impli-
cation tryptophan oxidation, at corresponding levels of
immune deficiency.
There are two feasible reasons for higher pro-
inflammatory activity in low-income sub-Saharan, and
more specific, low-income South African populations,
than in populations from the developed world. The first
would be a higher prevalence of infections, including
subclinical infections, and the second a higher preva-
lence of malnutrition, coupled to the effect of malnutri-
tion on the immune system.
The high prevalence of infections in sub-Saharan
countries is well-known [36]. Factors that contribute
to higher infection-related inflammatory activity in-
clude the presence of untreated clinical and subclinical
opportunistic infections, higher levels of health-care-
associated (nosocomial) infections, lower availability of
medical resources, as well as variable accessibility and ad-
herence to medications [37–42]. While the physician/
Table 3 Neopterin levels in HIV patients compared to that of HIV patients from populations of developed countries
Total patient groups At lower CD4 At higher CD4
Study NPT CD4 NPT CD4 NPT CD4
Present study 45.6 258.0 cells/μl 70.5 <200 cells/μl 24.1 >200 cells/μl
Schroeksnadel et al. 2008 [6] 14.1 404 cells/mm3 - - - -
Zangerle et al. 2002 [8] 23.4 112 cells/μl 23.4 112 cells/μl 8.0 232 cells/μl
Mildvan et al. 2005 [57] 16.0 75 cells/ml 20.4 50 cells/ml 9.9 200 cells/ml
Hanna et al. 2009 [58] - - 24.4 <200 cells/μl 12.5 >200 cells/μl
Kurz et al. 2009 [59] 25.0 204 cells/mm3 - - - -
Bogner et al. 1988 [60] - - 29.7 264 cells/μl 14.4 487 cells/μl
NPT neopterin (nmol/l)
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patient ratio in the developed world varies around 4 doc-
tors per 1000 patients, the South African ratio is estimated
to be about 0.8 doctors per 1000 patients, with even lower
ratios at state hospitals [43, 44]. Another factor that may
have an influence is the stage of the disease at which
HAART is initiated [45]. In contrast to American guide-
lines which suggest initiation of HAART at CD4 < 500
cells/μl, the South African Government guidelines recom-
mend initiation at CD4 cell counts <350 cells/μl [46, 47].
The second potential contributor to a higher level of
inflammatory activity, in the low-income population of
this study, is the effect of malnutrition on the immune
system [48]. It is known that malnutrition can lead to
increases in inflammatory mediators such as pro-
inflammatory cytokines and in the levels of the acute
phase protein CRP [48].
Tryptophan depletion is part of the general immune-
induced effects on the nutritional status of HIV infection
and AIDS
The effects of inflammation on nutritional status, i.e.,
disease-related malnutrition, as well as the low responsive-
ness of disease-related malnutrition to nutrient supple-
mentation, are well-described in a number of recent
publications [49–52]. Although a multitude of studies
have been published on the nutritional status of patients
with HIV infection and AIDS [23, 53], the fact that most
indicators of nutritional status are adversely influenced by
the activity of pro-inflammatory cytokines [49, 51, 54–56]
is generally overlooked. The malnutrition profile is thus
often described only in terms of food insecurity. In the
present study, the effects of HIV-induced inflammation
on indicators of the nutritional profile, such as albumin,
haemoglobin, the albumin/globulin (A/G) ratio, red cell
distribution width (RDW) and BMI [49, 51, 54–56], are
confirmed by the negative correlations found between the
levels of these indicators and that of the pro-inflammatory
markers neopterin, IL-6 and CRP (Table 2). Tryptophan
levels, as discussed in earlier paragraphs, similarly de-
clined with increases in inflammatory activity. Moreover,
highly significant correlations were seen between trypto-
phan levels and levels of the nutritional markers albumin,
haemoglobin, the A/G ratio and RDW (Table 2)—implying
associations between the inflammation-induced disturb-
ance in tryptophan levels and that of known markers of
nutritional status. We thus contend that tryptophan de-
pletion as a result of increased oxidation in the kynurenine
pathway in HIV-infected patients forms part of the general
immune-induced alterations in the nutritional status.
Conclusions
Tryptophan levels in HIV-infected and AIDS patients
are markedly lower in low-income, sub-Saharan HIV-
infected populations than in populations from developed
countries. Food insecurity and higher levels of inflamma-
tory activity are the most probable causes. We contend
that tryptophan depletion, due to oxidation in the kynur-
enine pathway, should be seen as part of the much wider
effect of pro-inflammatory activity on the nutritional
profile of HIV-infected patients.
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